Talquetamab, a Novel Anti-Myeloma GPRC5DxCD3 Bispecific Antibody, is Associated with Increased Oropharyngeal FDG Uptake

被引：0
|
作者：
Trak, J. [1 ]
Mouhieddine, T. [1 ]
Lancman, G. [1 ]
Sanchez, L. [1 ]
Chari, A. [1 ]
Ghesani, M. [1 ]
机构：
[1] Mt Sinai Hosp, New York, NY USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0351
引用
收藏
页码：S571 / S571
页数：1
相关论文
共 50 条
  • [1] Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
    Verkleij, Christie P. M.
    Broekmans, Marloes E. C.
    van Duin, Mark
    Frerichs, Kristine A.
    Kuiper, Rowan
    de Jonge, A. Vera
    Kaiser, Martin
    Morgan, Gareth
    Axel, Amy
    Boominathan, Rengasamy
    Sendecki, Jocelyn
    Wong, Amy
    Verona, Raluca, I
    Sonneveld, Pieter
    Zweegman, Sonja
    Adams, Homer C., III
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    BLOOD ADVANCES, 2021, 5 (08) : 2196 - 2215
  • [2] Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
    Purcell, Kiah
    Catamero, Donna
    Dai, Victoria
    Feuer, Julia
    Giacoia, Leora
    Leon, Yan
    Lurie, Alaina
    Mitchell, Emily
    Ray, Chloe
    Urena, Annel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S313
  • [3] MANAGEMENT CONSIDERATIONS FOR DERMATOLOGIC TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Esler, Elaine
    Ray, Chloe
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Gray, Kathleen
    McCluggage, Julie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [4] MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Shenoy, Samantha
    Leahey, Sheryl
    Catamero, Donna
    O'Rourke, Lisa
    Gray, Kathleen
    Rogers, Stephanie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [5] Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1
    Catamero, Donna
    Purcell, Kiah
    Ray, Chloe
    Giacoia, Leora
    Leahey, Sheryl
    Born, Patricia
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S314 - S315
  • [6] Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma
    Verkleij, Christie
    Broekmans, Marloes
    van Duin, Mark
    Frerichs, Kristine
    Kuiper, Rowan
    Kaiser, Martin
    Morgan, Gareth
    Axel, Amy
    Chiu, Chris
    Sonneveld, Pieter
    Zweegman, Sonja
    Adams, Homer, III
    Mutis, Tuna
    Van de Donk, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E122 - E123
  • [7] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
    Schinke, Carolina D.
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Rasche, Leo
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Ma, Xuewen
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara J.
    Hilder, Brandi
    Tolbert, Jaszianne A.
    Renaud, Thomas
    Goldberg, Jenna
    Heuck, Christoph
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A novel Immunotherapy Combination in relapsed/refractory Multiple Myeloma: Updated Analysis of Phase 1b Data for Talquetamab, a GPRC5DxCD3 bispecific Antibody, in Combination with Daratumumab
    Kortuem, K. M.
    Bahlis, N.
    Mateos, M. -V.
    Weisel, K.
    Dholaria, B.
    Garfall, A.
    Goldschmidt, H.
    Martin, T.
    Morillo, D.
    Reece, D.
    Hurd, D.
    Rodriguez-Otero, P.
    Bhutani, M.
    D'Souza, A.
    Oriol, A.
    Askari, E.
    San-Miguel, J.
    van de Donk, N.
    Vishwamitra, D.
    Lin, Wang S. X.
    Prior, T.
    Vandenberk, L.
    Smit, Damiette M. -A.
    Goldberg, J.
    Waesch, R.
    Chari, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 144 - 145
  • [9] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
    Schinke, C.
    Touzeau, C.
    Minnema, M. C.
    van de Donk, N. W.
    Rodriguez-Otero, P.
    Mateos, M. -V.
    Rasche, L.
    Ye, J. C.
    Vishwamitra, D.
    Ma, X.
    Qin, X.
    Campagna, M.
    Masterson, T.
    Hilder, B.
    Tolbert, J.
    Renaud, T.
    Goldberg, J.
    Heuck, C.
    Chari, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
  • [10] Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study
    Shkury, Eden
    Hellou, Tamer
    Nevo, Lee
    Avigdor, Abraham
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S88 - S89
12345